The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported ...

In clinical trials, researchers found Yeztugo to be highly effective as a twice-yearly form of pre-exposure prophylaxis.

Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...

On Wednesday, the Food and Drug Administration approved a highly effective, injectable drug to help prevent the transmission ...

But the Trump administration’s cuts to HIV programs in the U.S. and abroad could undermine the drug’s rollout.

A drug called lenacapavir, administered in two injections a year, offers protection from HIV comparable to daily pills. One ...

While cancelled NIH grants and regulatory uncertainty are less hospitable to clinical research in the U.S., Europe must play ...

A new twice-yearly shot could be a "game changer" in the fight against AIDS, but experts' hopes have dimmed because of the ...

Now, a groundbreaking study from researchers at Boston Children’s Hospital and Harvard Medical School is offering a potential new path forward: using already FDA-approved migraine medications to ...

The first patient enrolled in a planned international clinical trial has been treated at HonorHealth Research Institute with a new type of immune therapy for those with a rare muscle-weakness disease ...

AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of ...